Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sirtris, a GSK Company
With
GlaxoSmithKline
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mild to moderately active ulcerative colitis as evidenced by Mayo score 6-10 (inclusive) with rectal bleeding score ≥1, endoscopy score between 2-3 (inclusive), and physician's rating of disease activity \<3 at Day -5
Colonic inflammation extending proximal to the rectum (i.e., greater than 15 cm in extent) on baseline sigmoidoscopy at Day -5
Confirmed diagnosis of ulcerative colitis for at least 3 months prior to the Screening Visit (Visit 1)
Male or female between 18 and 75 years, inclusive
Body weight \>50 kg and BMI ≥18 kg/m\^2 at Screening (Visit 1)
Capable of giving written informed consent, and willing and able to comply with the requirements of the protocol
Female subjects of child-bearing potential must be willing to use reliable contraception from Visit 1 through the follow-up visit (Day 70)
You may not be if
Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, segmental colitis associated with diverticulosis, ischemic colitis, or radiation-induced colitis based on medical history, endoscopy, and/or histological findings
Presence of infectious colitis as evidenced by positive stool culture for enteric pathogens or positive stool Clostridium difficile cytotoxin assay at Visit 1
Presence of chronic liver disease, with the exception of known Gilbert's syndrome
A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody or HIV at Visit 1
Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures or compromise the subject's safety
History of malignant neoplasm within the past 5 years, other than localized basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ that has been resected or definitively treated with standard approaches
Prior diagnosis of flat colonic dysplasia or unresected raised colonic dysplasia (adenoma-like lesion or mass)
History of regular alcohol consumption within 6 months of the Screening (Visit 1) defined as an average weekly intake of \>14 drinks (one drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits) or presence of recreational drug abuse or dependence
Known bleeding disorders
Bowel surgery within 12 months prior to Visit 1
History of colectomy or partial colectomy
Treatment with oral aminosalicylates at doses \>4.8 g per day or aminosalicylate dose modification (except transient shift lasting up to 3 days) within 4 weeks prior to study Day -5 (Note: if on this type of treatment, the dose must remain constant throughout the study treatment period)
Treatment with rectal aminosalicylates at any dose within 2 weeks of study Day -5
Treatment with systemic or rectal corticosteroids within 4 weeks of study Day -5
Treatment with TNFα inhibitors or other biologics within 2 months prior to study Day -5
Treatment with other immunosuppressants (azathioprine or 6-mercaptopurine), if initiated within 3 months prior to study Day -5, or if changed in terms of dose within 3 months prior to study Day -5 (Note: if on this type of treatment, the dose must remain constant throughout the study treatment period)
Regular use of pro-biotic or prebiotic preparations within 4 weeks of study Day -5 visit
Regular use of non-steroidal anti-inflammatories (NSAIDS) or aspirin, except low dose (cardioprotective ≤325 mg/day) aspirin, within 7 days prior to study Day -5
Participation in a clinical trial and treatment with an study drug within 3 months prior to Visit 1
Have a clinically significant finding on a chest X-ray performed at Visit 1 or within 3 months of Visit 1
Have an abnormal 12-lead electrocardiogram (ECG) with one or more changes considered to be clinically significant on medical review
Renal or liver impairment based on laboratory values obtained at Visit 1 and defined as:
* serum creatinine level of ≥1.4 mg/dL for females and ≥1.5 mg/dL for males, or
* AST and/or ALT ≥2x upper limit of normal (ULN), or
* bilirubin \> 1.5xULN (an isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%)
* Hemoglobin less than 8.5 g/dL at Visit 1
* Have any other reason which, in the opinion of the investigator, would confound the conduct or interpretation of the study
Clareo Health | A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
